Health
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma – Newswise
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
A new kind of therapy
Brentuximab vedotin is an anti-CD30 antibody drug conjugate. The drug, which is already approved to treat adults with Hodgkin lymphoma, is targeted specifically to Hodgkin Reed Sternberg cells (cancer cells in Hodgkin lymphoma). Brentuximab vedotin delivers the medicine directly where it is needed.
“I think of brentuximab vedotin as a smart drug,” said first and corresponding author Monika Metzger, M.D., St. Jude Departments of Oncology and Global Pediatric Medicine. “Unlike conventional chemotherapy, which…
-
Noosa News17 hours agoAustralian Idol 2025 winner draws crowd for Noosa pop up show
-
General16 hours agoNew US tariffs on semiconductors coming ‘over the next week’, Donald Trump says
-
General20 hours agoLachlan Galvin to leave Wests Tigers at end of 2026 after knocking back record contract extension
-
General20 hours agoThe Left’s eternal war against private schools